Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.38 |
| ▸ | NQO2 | P16083 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742536 | 0.87 | EPHX2 (0.40) | L3MBTL1TSHRFFAR1EPHX2NR1H4 | |
| SCHEMBL11290858 | 0.80 | TAAR1 (0.41) | NQO2SMN1; SMN2TSHRKDM4EHSD17B10 | |
| SCHEMBL28872057 | 0.78 | L3MBTL1 (0.39) | L3MBTL1TSHRFFAR1 | |
| SCHEMBL19742597 | 0.78 | MTNR1A (0.33) | MTNR1AMTNR1BNQO2HSP90AA1SMN1; SMN2 | |
| SCHEMBL30279896 | 0.78 | MTNR1A (0.33) | MTNR1AMTNR1BNQO2HSP90AA1SMN1; SMN2 | |
| SCHEMBL19742636 | 0.78 | CYP19A1 (0.34) | MTNR1AMTNR1BL3MBTL1SMN1; SMN2TSHR | |
| SCHEMBL1028248 | 0.76 | MAPT (0.35) | MTNR1AMTNR1BNQO2SMN1; SMN2TSHR | |
| SCHEMBL19212130 | 0.76 | AKR1B1 (0.44) | FFAR1 | |
| SCHEMBL6675153 | 0.75 | MTNR1A (0.49) | MTNR1AMTNR1B | |
| SCHEMBL30279930 | 0.74 | LMNA (0.36) | L3MBTL1HSP90AA1SMN1; SMN2DHFRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | MTNR1A 850/4885MTNR1B 891/4885NQO2 727/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | MTNR1A 850/4885MTNR1B 891/4885NQO2 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.